Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis

D Datta, S Jamwal, N Jyoti, S Patnaik… - The FEBS …, 2024 - Wiley Online Library
The emergence of antimicrobial resistance (AMR) across bacterial pathogens presents a
serious threat to global health. This threat is further exacerbated in tuberculosis (TB), mainly …

Unlocking the enigma of phenotypic drug tolerance: Mechanisms and emerging therapeutic strategies

AK Mishra, RP Thakare, BG Santani, SM Yabaji… - Biochimie, 2023 - Elsevier
In the ongoing battle against antimicrobial resistance, phenotypic drug tolerance poses a
formidable challenge. This adaptive ability of microorganisms to withstand drug pressure …

[HTML][HTML] Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles

S Fan, D Zhao, J Wang, Y Ma, D Chen, Y Huang… - Materials Today Bio, 2024 - Elsevier
Tuberculosis (TB) remains the leading cause of deaths among infectious diseases
worldwide. Cutaneous Tuberculosis (CTB), caused by Mycobacterium tuberculosis (Mtb) …

A virulence-associated small RNA MTS1338 activates an ABC transporter CydC for rifampicin efflux in Mycobacterium tuberculosis

S Singh, T Dutta - Frontiers in Microbiology, 2024 - frontiersin.org
The efficacy of the tuberculosis treatment is restricted by innate drug resistance of
Mycobacterial tuberculosis and its ability to acquire resistance to all anti-tuberculosis drugs …

A Dose‐Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis

C Padmapriyadarsini, JD Szumowski… - Clinical …, 2024 - Wiley Online Library
Induction of mycobacterial efflux pumps is a cause of Mycobacterium tuberculosis (Mtb) drug
tolerance, a barrier to shortening antitubercular treatment. Verapamil inhibits Mtb efflux …

PDCD4 as a marker of mTOR pathway activation and therapeutic target in mycobacterial infections

R Paroha, J Wang, S Lee - Microbiology Spectrum, 2024 - journals.asm.org
Programmed cell death protein 4 (PDCD4) is instrumental in regulating a range of cellular
processes such as translation, apoptosis, signal transduction, and inflammatory responses …

P-glycoprotein inhibitors as an adjunct therapy for TB

KK Parida, M Lahiri, M Ghosh, A Dalal, NP Kalia - Drug Discovery Today, 2024 - Elsevier
Highlights•The action of the efflux pump contributes to MDR-TB cases.•P-glycoprotein
reduces the bioavailability of anti-TB drugs.•Upregulation of angiogenic factors and P-gp …

Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis

C Dong, Y Wang, Y Cai, Y Wu, W Chen… - Drug Design …, 2024 - Taylor & Francis
Purpose Tuberculosis (TB) remains a major health threat worldwide, and the spread of drug-
resistant (DR) TB impedes the reduction of the global disease burden. Ebselen (EbSe) …

Bacterial efflux pumps excrete SYTO™ dyes and lead to false-negative staining results

GAS Minero, PB Larsen, ME Hoppe, RL Meyer - Analyst, 2024 - pubs.rsc.org
Multidrug efflux pumps excrete a range of small molecules from bacterial cells. In this study,
we show that bacterial efflux pumps have affinity for a range of SYTO™ dyes that are …

Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis

EG Ufimtseva, NI Eremeeva - International Journal of Molecular Sciences, 2023 - mdpi.com
The rapid spread of drug-resistant M. tuberculosis (Mtb) strains and the phenomenon of
phenotypic tolerance to drugs present challenges toward achieving the goal of tuberculosis …